Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae118 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2024. Verfasst von Jacob K Jamison und 6 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medical College, New York, NY, United States. Hauptthemen laut MEDLINE: Pyridines, Benzamides, Neuroendocrine Tumors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms with an increasing annual incidence and prevalence. Many are metastatic at presentation or recur following surgical resection and require systemic therapy, for which somatostatin analogs such as octreotide or lanreotide comprise typical first-line therapies. Nonetheless, treatment options remain limited. Epigenetic processes such as histone modifications have been implicated in malignant transformation and progression. In this study, we evaluated the anti-proliferative effects of a histone deacetylase (HDAC) inhibitor, entinostat, which was computationally predicted to show anti-cancer activity, as confirmed in in vitro and in vivo models of GEP-NETs.
Methods
This was a phase II study to evaluate the efficacy and safety of entinostat in patients with relapsed or refractory abdominal NETs. The primary objective was to estimate the objective response rate to entinostat. Additionally, with each patient as his/her own control we estimated the rates of tumor growth prior to enrollment on study and while receiving entinostat. Patients received 5 mg entinostat weekly until disease progression or intolerable toxicity. The dose could be changed to 10 mg biweekly for patients who did not experience grade ≥ 2 treatment-related adverse events (AEs) in cycle 1, but was primarily administered at the starting 5 mg weekly dose.
Results
The study enrolled only 5 patients due to early termination by the drug sponsor. The first patient that enrolled had advanced disease and died within days of enrollment before follow-up imaging due to a grade 5 AE unrelated to study treatment and was considered non-evaluable. Best RECIST response for the remaining 4 patients was stable disease (SD) with time on study of 154+, 243, 574, and 741 days. With each patient as his/her own control, rates of tumor growth on entinostat were markedly reduced with rates 17%, 20%, 33%, and 68% of the rates prior to enrollment on study. Toxicities possibly or definitely related to entinostat included grade 2/3 neutrophil count decrease [2/4 (50%)/ 2/4 (50%)], grade 3 hypophosphatemia [1/4, (25%)], grade 1/2 fatigue [1/4 (25%)/ 2/4 (50%)], and other self-limiting grade 1/2 AEs.
Conclusion
In the treatment of relapsed or refractory abdominal NETs, entinostat 5 mg weekly led to prolonged SD and reduced the rate of tumor growth by 32% to 83% with an acceptable safety profile (ClinicalTrials.gov Identifier: NCT03211988).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medical College, New York, NY, United States.
- Department of Medicine, Division of Hematology Oncology, Columbia University Irving Medical Center, New York, NY, United States.
- University of Arizona Cancer Center, Tucson, AZ, United States.
- Department of Radiology, Columbia University Irving Medical Center, New York, NY, United States.
- Department of Systems Biology, Columbia University Irving Medical Center, New York, NY, United States.
- Department of Biochemistry and Molecular Biophysics, Columbia University Irving Medical Center, New York, NY, United States.
ORCID-Profile: Jacob K Jamison
Förderung
- NIH HHS
- NCI NIH HHS
Zitieren
APA
Jamison, J. K., Zhou, M., Gelmann, E. P., Luk, L., Bates, S. E., Califano, A., & Fojo, T. (2024). Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. The Oncologist. https://doi.org/10.1093/oncolo/oyae118
Vancouver
Jamison JK, Zhou M, Gelmann EP, Luk L, Bates SE, Califano A, et al. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. The Oncologist. 2024. doi:10.1093/oncolo/oyae118
BibTeX
@article{Jamison2024,
author = {Jamison, Jacob K and Zhou, Mengxi and Gelmann, Edward P and Luk, Lyndon and Bates, Susan E and Califano, Andrea and Fojo, Tito},
title = {Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae118}
}
EUVIMED